Mikael Dolsten

620 total citations · 1 hit paper
16 papers, 316 citations indexed

About

Mikael Dolsten is a scholar working on Economics and Econometrics, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Mikael Dolsten has authored 16 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Economics and Econometrics, 4 papers in Molecular Biology and 3 papers in Infectious Diseases. Recurrent topics in Mikael Dolsten's work include Pharmaceutical Economics and Policy (4 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and Biotechnology and Related Fields (3 papers). Mikael Dolsten is often cited by papers focused on Pharmaceutical Economics and Policy (4 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and Biotechnology and Related Fields (3 papers). Mikael Dolsten collaborates with scholars based in United States, Switzerland and Netherlands. Mikael Dolsten's co-authors include Charles H. Jones, Kathrin U. Jansen, Prakash S. Naik, Gianluca Nucci, Sandeep Menon, N. So, John R. Androsavich, Michael S. Vincent, Charlotte Allerton and Verna Welch and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Nature Biotechnology.

In The Last Decade

Mikael Dolsten

15 papers receiving 304 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Healthcare on the brink: navigating the challenges of an aging society in the United States

2024 87 citations Charles H. Jones, Mikael Dolsten PubMed profile →

Peers

Countries citing papers authored by Mikael Dolsten

Since Specialization

Citations

This map shows the geographic impact of Mikael Dolsten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikael Dolsten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikael Dolsten more than expected).

Fields of papers citing papers by Mikael Dolsten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikael Dolsten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikael Dolsten. The network helps show where Mikael Dolsten may publish in the future.

Co-authorship network of co-authors of Mikael Dolsten

This figure shows the co-authorship network connecting the top 25 collaborators of Mikael Dolsten. A scholar is included among the top collaborators of Mikael Dolsten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mikael Dolsten. Mikael Dolsten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	The unprecedented Paxlovid journey from milligrams to millions of patient doses during the Covid-19 pandemic 2025 ·Communications Medicine ·Weili Yu, (unknown), (unknown), Ravi Shanker, Pratik Doshi, John A. Ragan, Robert A. Greene, (unknown), Stéphane Caron, (unknown), John A. Ludwig, Mikael Dolsten	4
2	Unlocking disease insights to facilitate drug development: Pharmaceutical industry–academia collaborations in inflammation and immunology 2025 ·Drug Discovery Today ·Elena Peeva, Emma Guttman‐Yassky, Yuji Yamaguchi, Brian Berman, Barry S. Oemar, Jyoti Ramakrishna, Alessio Fasano, Carmella Evans‐Molina, Myron Chu, Benjamin Ungar, Pércío S. Gulko, María Padilla, (unknown), Arezou Khosroshahi, Patrick M. Brunner, (unknown), Michael S. Vincent, Mikael Dolsten	1
3	Challenges and prospects in precision medicine with RNA-based biocatalysts 2025 ·Nature Catalysis ·Charles H. Jones, Mikael Dolsten	0
4	Framework to identify innovative sources of value creation from platform technologies 2025 ·Proceedings of the National Academy of Sciences ·Charles H. Jones, (unknown), Andrew Hill, D M Griffiths, Matthew Murphy, (unknown), Mikael Dolsten, (unknown)	2
5	Breaking the mold with RNA—a “RNAissance” of life science 2024 ·npj Genomic Medicine ·Charles H. Jones, John R. Androsavich, N. So, (unknown), (unknown), (unknown), Verna Welch, (unknown), Mikael Dolsten	32
6	Healthcare on the brink: navigating the challenges of an aging society in the United States breakdown → 2024 ·PubMed ·Charles H. Jones, Mikael Dolsten	87
7	Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development 2024 ·Drug Discovery Today ·Elena Peeva, Anindita Banerjee, Christopher Banfield, Koshika Soma, Jared Christensen, Sandeep Menon, Michael S. Vincent, Mikael Dolsten	3
8	Rewriting the textbook for pharma: how to adapt and thrive in a digital, personalized and collaborative world 2024 ·Drug Discovery Today ·Charles H. Jones, Subha Madhavan, Natarajan Kannan, (unknown), (unknown), Mikael Dolsten	3
9	Deciphering immune responses: a comparative analysis of influenza vaccination platforms 2024 ·Drug Discovery Today ·Charles H. Jones, (unknown), (unknown), (unknown), Verna Welch, Kelly Lindert, (unknown), (unknown), Mikael Dolsten	4
10	Delivering 3 billion doses of Comirnaty in 2021 2023 ·Nature Biotechnology ·Nicholas W. Warne, Margaret Ruesch, (unknown), Paul Kojo Mensah, John A. Ludwig, (unknown), Ranga Godavarti, (unknown), Mikael Dolsten	23
11	Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir 2022 ·Clinical Infectious Diseases ·Emily S. Ford, William Simmons, Ellora Karmarkar, (unknown), (unknown), Johnnie J. Orozco, (unknown), (unknown), (unknown), Joshua O. Benditt, Pavitra Roychoudhury, Alexander L. Greninger, Adrienne E. Shapiro, Jennifer Hammond, James M. Rusnak, Mikael Dolsten, Michael Boeckh, Catherine Liu, Guang‐Shing Cheng, Lawrence Corey	40
12	Innovation in breakthrough drugs and vaccines: Development risk, patient impact, and value 2021 ·Drug Discovery Today ·Andrew E. Prigodich, (unknown), Patrick R. Verhoest, Nicholas W. Warne, Charlotte Allerton, John E. Burkhardt, (unknown), Mikael Dolsten	2
13	Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity 2021 ·Drug Discovery Today ·(unknown), Sandeep Menon, Kathrin U. Jansen, Prakash S. Naik, Gianluca Nucci, (unknown), (unknown), Mikael Dolsten	32
14	Reviving an R&D pipeline: a step change in the Phase II success rate 2020 ·Drug Discovery Today ·(unknown), (unknown), Charlotte Allerton, Kathrin U. Jansen, Michael S. Vincent, Mikael Dolsten	24
15	Precision medicine in the age of big data: The present and future role of large‐scale unbiased sequencing in drug discovery and development 2015 ·Clinical Pharmacology & Therapeutics ·P. Vicini, (unknown), Eric Lai, E. David Litwack, (unknown), (unknown), (unknown), Marisa Papaluca, (unknown), Michael S. Ringel, Mark E. Robson, H. Sakul, Joseph G. Vockley, Tal Zaks, Mikael Dolsten, Morten Søgaard	31
16	Precision medicine: an approach to R&D for delivering superior medicines to patients 2012 ·SHILAP Revista de lepidopterología ·Mikael Dolsten, (unknown)	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact